Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
ADVM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.78 - $8.56
Previous CloseN/A
Volume79.70K
Average Volume (3M)522.06K
Market Cap
$103.66M
Enterprise Value$93.00M
Total Cash (Recent Filing)$44.40M
Total Debt (Recent Filing)$92.22M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Nov 06, 2025EPS Estimate
-1.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding20,984,161
10 Day Avg. Volume427,221
30 Day Avg. Volume522,056
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue93.00
Enterprise Value/Gross Profit-7.91
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$15.00Price Target Upside207.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company announced the completion of wet AMD patient screening for its pivotal Phase 3 ARTEMIS trial ahead of expectations, indicating strong demand for their novel gene therapy.
Earnings PotentialShares are substantially undervalued for the potential of the therapy's second Phase III.
Bears Say
Cash RunwayThere is a financing overhang with cash and equivalents expected to fund operations into the fourth quarter of 2025, particularly in an investment environment that underappreciates novel gene therapy treatments.
Funding ChallengesThe need for financing and/or partnership to support ongoing pivotal Ixo-vec development across both the current Phase 3 ARTEMIS trial, and the forthcoming Phase 3 AQUARIUS trial is a concern among investors.
Adverum Biotechnologies News
ADVM FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest stock price was $1.78 and its highest was $8.56 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Adverum Biotechnologies’s market cap is $103.66M.
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is Nov 06, 2025 which is in 27 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Aug 12, 2025. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$2.247 by -$0.093.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate is -1.76.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,984,161 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$2.34 in its last earnings report, missing expectations of -$2.247. Following the earnings report the stock price went up 10.268%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Currently, no hedge funds are holding shares in ADVM
Adverum Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (207.38% Upside)
$15.00 (207.38% Upside)
Blogger Sentiment
Bullish
ADVM Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 34.4%
Last 30 Days ▲ 172.6%
Last 30 Days ▲ 172.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.60%
12-Months-Change
Fundamentals
Return on Equity
-222.28%
Trailing 12-Months
Asset Growth
-62.10%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
ADVM Stock 12 Month Forecast
Average Price Target
$15.00
▲(207.38% Upside)
Technical Analysis
MacroGenics
―
Armata Pharmaceuticals
―
VistaGen Therapeutics
―
Kalaris Therapeutics
―
Nautilus Biotechnolgy
―
Ownership Overview
22.11% Insiders
13.38% Mutual Funds
0.40% Other Institutional Investors
53.98% Public Companies and
Individual Investors